Catalysts made and planned for 2022
About Citius Pharmaceuticals, Inc.
Citius is a late-stage biopharmaceutical company committed to advancing and commercializing world-class critical care products, with a focus on oncology, anti-infectives in complementary cancer care, proprietary prescription products, and mobile stem therapies. The company has two late-stage product candidates, Mino-Lok®, an antibiotic lock solution for treating patients with catheter-related bloodstream infections (CRBSI), which is recently enrolling patients in a pivotal superiority trial and I/ONTAK (E7777), a new IL-2R immunotherapy for an initial indication in cutaneous T-mobile lymphoma (CTCL), which has completed enrollment in its pivotal phase 3 trial. Mino-Lok ® has earned Fast Track designation from the US Food and Drug Administration (FDA). I/ONTAK has earned orphan drug designation from the FDA for the treatment of CTCL and peripheral T-cell lymphoma (PTCL). Through its subsidiary, NoveCite, Inc. , Citius is introducing a new patented remedy based on a mesenchymal stem cell derived from induced pluripotent stem cells (iPSC) for acute respiratory conditions, with a short-term focus on respiratory distress (ARDS) related to COVID-19. For more information, make a stop at www. citiuspharma. com.
Safe Harbor
Citius Pharmaceuticals Investor Relations:Ilanit AllenVice President of Investor Relations and Corporate CommunicationsT: 908-967-6677 x113E: ir@citiuspharma. com
View content to download media: https://www. prnewswire. com/news-releases/citius-pharmaceuticals-inc-provides-business-update-highlights-upcoming-milestones-301538553. html
SOURCECitius Pharmaceuticals, Inc.